m1 with lps Search Results


mouse tlr4 expression  (OriGene)
90
OriGene mouse tlr4 expression
Activity of an NF‐κB reporter relative to vehicle control in human embryonic kidney cells that express <t>TLR4</t> (hTLR4) or an isogenic control cell line that does not express TLR4 (null2) and were stimulated with vehicle (veh), 1 ng/ml LPS, 400 µM nickel chloride, or 25, 50, or 100 µM platinum(II) chloride, and platinum(IV) chloride ( n = 3 independent biological replicates). As per panel (A), secreted IL‐8 was monitored as a metric of TLR4 activation upon stimulation with 50 pg/ml LPS, 200 µM nickel chloride, 100 µM platinum(II) chloride, or 100 µM platinum(IV) chloride ( n = 4 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 and HEK‐null2 cells following treatment with cisplatin at the indicated concentrations ( n = 3 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 cells pre‐treated with 4 µ M TAK242 (TLR4 inhibitor) or vehicle, and subsequent treatment with 50 pg/ml LPS, 200 µM nickel chloride, or 25 µM cisplatin ( n = 3 independent biological replicates). Mock cells were not subject to pre‐treatment prior to agonist addition. Data Information: For all panels, actual individual data from each experiment are plotted as box (25 th and 75 th percentile borders; median central band) with Tukey whiskers. Statistical analyses were assessed by 2‐way ANOVA: in (A) hTLR4 compared to null2 cells; in (B) agonist treatment compared to non‐treated ( nil ); in (C) comparisons between successive concentrations; and in (D) comparisons between vehicle and TAK‐242 treatments. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Dunnett’s test, A, B, D; Tukey test, C). Source data are available online for this figure.
Mouse Tlr4 Expression, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/m1+with+lps/Tlr4+(NM_021297)+Mouse+Tagged+ORF+Clone/pmc08097357-272-6-10
Average 90 stars, based on 1 article reviews
mouse tlr4 expression - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
tlr genes are tlr4  (OriGene)
90
OriGene tlr genes are tlr4
Activity of an NF‐κB reporter relative to vehicle control in human embryonic kidney cells that express <t>TLR4</t> (hTLR4) or an isogenic control cell line that does not express TLR4 (null2) and were stimulated with vehicle (veh), 1 ng/ml LPS, 400 µM nickel chloride, or 25, 50, or 100 µM platinum(II) chloride, and platinum(IV) chloride ( n = 3 independent biological replicates). As per panel (A), secreted IL‐8 was monitored as a metric of TLR4 activation upon stimulation with 50 pg/ml LPS, 200 µM nickel chloride, 100 µM platinum(II) chloride, or 100 µM platinum(IV) chloride ( n = 4 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 and HEK‐null2 cells following treatment with cisplatin at the indicated concentrations ( n = 3 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 cells pre‐treated with 4 µ M TAK242 (TLR4 inhibitor) or vehicle, and subsequent treatment with 50 pg/ml LPS, 200 µM nickel chloride, or 25 µM cisplatin ( n = 3 independent biological replicates). Mock cells were not subject to pre‐treatment prior to agonist addition. Data Information: For all panels, actual individual data from each experiment are plotted as box (25 th and 75 th percentile borders; median central band) with Tukey whiskers. Statistical analyses were assessed by 2‐way ANOVA: in (A) hTLR4 compared to null2 cells; in (B) agonist treatment compared to non‐treated ( nil ); in (C) comparisons between successive concentrations; and in (D) comparisons between vehicle and TAK‐242 treatments. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Dunnett’s test, A, B, D; Tukey test, C). Source data are available online for this figure.
Tlr Genes Are Tlr4, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/m1+with+lps/Tlr4+(NM_021297)+Mouse+Tagged+ORF+Clone+Lentiviral+Particle/10__1523_slash_jneurosci__0870___12__2012-81-7-25
Average 90 stars, based on 1 article reviews
tlr genes are tlr4 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
nm 021297  (OriGene)
90
OriGene nm 021297
Activity of an NF‐κB reporter relative to vehicle control in human embryonic kidney cells that express <t>TLR4</t> (hTLR4) or an isogenic control cell line that does not express TLR4 (null2) and were stimulated with vehicle (veh), 1 ng/ml LPS, 400 µM nickel chloride, or 25, 50, or 100 µM platinum(II) chloride, and platinum(IV) chloride ( n = 3 independent biological replicates). As per panel (A), secreted IL‐8 was monitored as a metric of TLR4 activation upon stimulation with 50 pg/ml LPS, 200 µM nickel chloride, 100 µM platinum(II) chloride, or 100 µM platinum(IV) chloride ( n = 4 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 and HEK‐null2 cells following treatment with cisplatin at the indicated concentrations ( n = 3 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 cells pre‐treated with 4 µ M TAK242 (TLR4 inhibitor) or vehicle, and subsequent treatment with 50 pg/ml LPS, 200 µM nickel chloride, or 25 µM cisplatin ( n = 3 independent biological replicates). Mock cells were not subject to pre‐treatment prior to agonist addition. Data Information: For all panels, actual individual data from each experiment are plotted as box (25 th and 75 th percentile borders; median central band) with Tukey whiskers. Statistical analyses were assessed by 2‐way ANOVA: in (A) hTLR4 compared to null2 cells; in (B) agonist treatment compared to non‐treated ( nil ); in (C) comparisons between successive concentrations; and in (D) comparisons between vehicle and TAK‐242 treatments. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Dunnett’s test, A, B, D; Tukey test, C). Source data are available online for this figure.
Nm 021297, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/m1+with+lps/Tlr4+(NM_021297)+Mouse+Tagged+ORF+Clone/pmc03417042-77-14-29
Average 90 stars, based on 1 article reviews
nm 021297 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Activity of an NF‐κB reporter relative to vehicle control in human embryonic kidney cells that express TLR4 (hTLR4) or an isogenic control cell line that does not express TLR4 (null2) and were stimulated with vehicle (veh), 1 ng/ml LPS, 400 µM nickel chloride, or 25, 50, or 100 µM platinum(II) chloride, and platinum(IV) chloride ( n = 3 independent biological replicates). As per panel (A), secreted IL‐8 was monitored as a metric of TLR4 activation upon stimulation with 50 pg/ml LPS, 200 µM nickel chloride, 100 µM platinum(II) chloride, or 100 µM platinum(IV) chloride ( n = 4 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 and HEK‐null2 cells following treatment with cisplatin at the indicated concentrations ( n = 3 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 cells pre‐treated with 4 µ M TAK242 (TLR4 inhibitor) or vehicle, and subsequent treatment with 50 pg/ml LPS, 200 µM nickel chloride, or 25 µM cisplatin ( n = 3 independent biological replicates). Mock cells were not subject to pre‐treatment prior to agonist addition. Data Information: For all panels, actual individual data from each experiment are plotted as box (25 th and 75 th percentile borders; median central band) with Tukey whiskers. Statistical analyses were assessed by 2‐way ANOVA: in (A) hTLR4 compared to null2 cells; in (B) agonist treatment compared to non‐treated ( nil ); in (C) comparisons between successive concentrations; and in (D) comparisons between vehicle and TAK‐242 treatments. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Dunnett’s test, A, B, D; Tukey test, C). Source data are available online for this figure.

Journal: EMBO Reports

Article Title: Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity

doi: 10.15252/embr.202051280

Figure Lengend Snippet: Activity of an NF‐κB reporter relative to vehicle control in human embryonic kidney cells that express TLR4 (hTLR4) or an isogenic control cell line that does not express TLR4 (null2) and were stimulated with vehicle (veh), 1 ng/ml LPS, 400 µM nickel chloride, or 25, 50, or 100 µM platinum(II) chloride, and platinum(IV) chloride ( n = 3 independent biological replicates). As per panel (A), secreted IL‐8 was monitored as a metric of TLR4 activation upon stimulation with 50 pg/ml LPS, 200 µM nickel chloride, 100 µM platinum(II) chloride, or 100 µM platinum(IV) chloride ( n = 4 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 and HEK‐null2 cells following treatment with cisplatin at the indicated concentrations ( n = 3 independent biological replicates). IL‐8 secretion in HEK‐hTLR4 cells pre‐treated with 4 µ M TAK242 (TLR4 inhibitor) or vehicle, and subsequent treatment with 50 pg/ml LPS, 200 µM nickel chloride, or 25 µM cisplatin ( n = 3 independent biological replicates). Mock cells were not subject to pre‐treatment prior to agonist addition. Data Information: For all panels, actual individual data from each experiment are plotted as box (25 th and 75 th percentile borders; median central band) with Tukey whiskers. Statistical analyses were assessed by 2‐way ANOVA: in (A) hTLR4 compared to null2 cells; in (B) agonist treatment compared to non‐treated ( nil ); in (C) comparisons between successive concentrations; and in (D) comparisons between vehicle and TAK‐242 treatments. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Dunnett’s test, A, B, D; Tukey test, C). Source data are available online for this figure.

Article Snippet: HEI‐OC1 cells were transfected with a mouse Tlr4 expression clone (OriGene; MR210887) to test for complementation of the Tlr4 deletion strain.

Techniques: Activity Assay, Control, Activation Assay

IL‐8 secretion in HEK cells stably expressing hTLR4 but not MD‐2 (HEK‐isoTLR4), transfected with empty vector (EV) or MD‐2 and left untreated ( nil ) or treated with 1 ng/ml LPS, 200 µM nickel chloride, 2 µg/ml HMGB1, 100 µM platinum(II) chloride, 100 µM platinum(IV) chloride, or 25 µM cisplatin ( n = 3 or 4 independent biological replicates). Fold IL‐8 secreted (relative to nil treatment) in MD‐2‐deficient HeLa cells treated with 10 or 100 ng/ml LPS or 25 µM cisplatin ( n = 4 independent biological replicates). IL‐8 secretion in HeLa cells transfected with non‐targeting (siNT) or TLR4 ‐targeting (si TLR4 ) siRNA and left untreated ( nil ), or treated with 30 µM cisplatin ( n = 3 independent biological replicates). Mock cells were not subject to siRNA treatment prior. Data Information: Actual individual data are plotted as box (25 th and 75 th percentile borders; median central band) with Tukey whiskers (A, C) or mean and standard deviation (B). Statistical analyses were determined in comparison to nil treatments using 2‐way (A, C) or one‐way (B) ANOVA. ns, not significant; * P < 0.05; **** P < 0.0001 (Dunnett’s test). Source data are available online for this figure.

Journal: EMBO Reports

Article Title: Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity

doi: 10.15252/embr.202051280

Figure Lengend Snippet: IL‐8 secretion in HEK cells stably expressing hTLR4 but not MD‐2 (HEK‐isoTLR4), transfected with empty vector (EV) or MD‐2 and left untreated ( nil ) or treated with 1 ng/ml LPS, 200 µM nickel chloride, 2 µg/ml HMGB1, 100 µM platinum(II) chloride, 100 µM platinum(IV) chloride, or 25 µM cisplatin ( n = 3 or 4 independent biological replicates). Fold IL‐8 secreted (relative to nil treatment) in MD‐2‐deficient HeLa cells treated with 10 or 100 ng/ml LPS or 25 µM cisplatin ( n = 4 independent biological replicates). IL‐8 secretion in HeLa cells transfected with non‐targeting (siNT) or TLR4 ‐targeting (si TLR4 ) siRNA and left untreated ( nil ), or treated with 30 µM cisplatin ( n = 3 independent biological replicates). Mock cells were not subject to siRNA treatment prior. Data Information: Actual individual data are plotted as box (25 th and 75 th percentile borders; median central band) with Tukey whiskers (A, C) or mean and standard deviation (B). Statistical analyses were determined in comparison to nil treatments using 2‐way (A, C) or one‐way (B) ANOVA. ns, not significant; * P < 0.05; **** P < 0.0001 (Dunnett’s test). Source data are available online for this figure.

Article Snippet: HEI‐OC1 cells were transfected with a mouse Tlr4 expression clone (OriGene; MR210887) to test for complementation of the Tlr4 deletion strain.

Techniques: Stable Transfection, Expressing, Transfection, Plasmid Preparation, Standard Deviation, Comparison

TLR4 expression levels (relative to nil treatment) in HeLa cells transfected with non‐targeting (siNT) or TLR4 ‐targeting (si TLR4 ) siRNA molecules and treated with 30 µM cisplatin. Data information: Actual individual data from 2 independent experiments are plotted with mean and standard deviation indicated. Source data are available online for this figure.

Journal: EMBO Reports

Article Title: Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity

doi: 10.15252/embr.202051280

Figure Lengend Snippet: TLR4 expression levels (relative to nil treatment) in HeLa cells transfected with non‐targeting (siNT) or TLR4 ‐targeting (si TLR4 ) siRNA molecules and treated with 30 µM cisplatin. Data information: Actual individual data from 2 independent experiments are plotted with mean and standard deviation indicated. Source data are available online for this figure.

Article Snippet: HEI‐OC1 cells were transfected with a mouse Tlr4 expression clone (OriGene; MR210887) to test for complementation of the Tlr4 deletion strain.

Techniques: Expressing, Transfection, Standard Deviation

Comparison of genomic DNA at the Tlr4 locus from Tlr4 −/− HEI‐OC1 and wild‐type cells. Sequences from the Tlr4 −/− cell line contained a single nucleotide insertion or four nucleotide deletion and summarized below. Anti‐TLR4 staining in Tlr4 −/− and control HEI‐OC1 cells. Bars (lower right) are 50 µm. Flow cytometric analysis of conjugated LPS internalization in Tlr4 −/− and control HEI‐OC1 cells ( n = 4 independent biological replicates). IL‐6 secretion in Tlr4 −/− and control HEI‐OC1 cells transfected with empty vector (EV), Tlr4 (p Tlr4 ), or left untransfected (−) and subsequently treated with 100 ng/ml LPS ( n = 4 independent biological replicates). Inset , fold induction of IL‐6 secretion was determined relative to the untransfected cells treated with LPS. Data information: In (C and D), data are presented as mean and standard deviation. Statistical comparisons were assessed by 2‐way ANOVA (D). ** P < 0.01; **** P < 0.0001 (unpaired Student’s t ‐test, C; Bonferroni test, D). Source data are available online for this figure.

Journal: EMBO Reports

Article Title: Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity

doi: 10.15252/embr.202051280

Figure Lengend Snippet: Comparison of genomic DNA at the Tlr4 locus from Tlr4 −/− HEI‐OC1 and wild‐type cells. Sequences from the Tlr4 −/− cell line contained a single nucleotide insertion or four nucleotide deletion and summarized below. Anti‐TLR4 staining in Tlr4 −/− and control HEI‐OC1 cells. Bars (lower right) are 50 µm. Flow cytometric analysis of conjugated LPS internalization in Tlr4 −/− and control HEI‐OC1 cells ( n = 4 independent biological replicates). IL‐6 secretion in Tlr4 −/− and control HEI‐OC1 cells transfected with empty vector (EV), Tlr4 (p Tlr4 ), or left untransfected (−) and subsequently treated with 100 ng/ml LPS ( n = 4 independent biological replicates). Inset , fold induction of IL‐6 secretion was determined relative to the untransfected cells treated with LPS. Data information: In (C and D), data are presented as mean and standard deviation. Statistical comparisons were assessed by 2‐way ANOVA (D). ** P < 0.01; **** P < 0.0001 (unpaired Student’s t ‐test, C; Bonferroni test, D). Source data are available online for this figure.

Article Snippet: HEI‐OC1 cells were transfected with a mouse Tlr4 expression clone (OriGene; MR210887) to test for complementation of the Tlr4 deletion strain.

Techniques: Comparison, Staining, Control, Transfection, Plasmid Preparation, Standard Deviation

A–D HEI‐OC1 cells containing a Tlr4 deletion ( Tlr4 −/− ) were compared to HEI‐OC1 non‐targeting (NT) control cells and assessed for cell viability (A), Annexin V/propidium iodide staining (B), ROS generation (C), and IL‐6 secretion (D) following cisplatin treatment at the indicated concentrations ( n = 3 independent biological replicates). Data Information: In all panels, data are presented as mean and standard deviation. Statistical comparisons to NT at the same cisplatin concentration were assessed by 2‐way (A, B) or one‐way (C, D) ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Bonferroni test). Source data are available online for this figure.

Journal: EMBO Reports

Article Title: Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity

doi: 10.15252/embr.202051280

Figure Lengend Snippet: A–D HEI‐OC1 cells containing a Tlr4 deletion ( Tlr4 −/− ) were compared to HEI‐OC1 non‐targeting (NT) control cells and assessed for cell viability (A), Annexin V/propidium iodide staining (B), ROS generation (C), and IL‐6 secretion (D) following cisplatin treatment at the indicated concentrations ( n = 3 independent biological replicates). Data Information: In all panels, data are presented as mean and standard deviation. Statistical comparisons to NT at the same cisplatin concentration were assessed by 2‐way (A, B) or one‐way (C, D) ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Bonferroni test). Source data are available online for this figure.

Article Snippet: HEI‐OC1 cells were transfected with a mouse Tlr4 expression clone (OriGene; MR210887) to test for complementation of the Tlr4 deletion strain.

Techniques: Control, Staining, Standard Deviation, Concentration Assay

IL‐6 secretion in HEI‐OC1 cells treated with 100 pg/ml LPS or 20 µM cisplatin ( n = 3 or 4 independent biological replicates). IL‐6 secretion in TLR4 −/− cells transfected with empty vector (EV) or mouse Tlr4 (m Tlr4 ) following treatment with 20 µM cisplatin ( n = 6 independent biological replicates). Il6 and Tlr4 transcript levels in HEI‐OC1 cells following treatment with 20 µM cisplatin for the indicated times ( n = 3 independent biological replicates). Data information: In all panels, data are presented as mean and standard deviation. Statistical comparisons to 0 h time point were assessed by 2‐way ANOVA. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Dunnett’s test). Source data are available online for this figure.

Journal: EMBO Reports

Article Title: Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity

doi: 10.15252/embr.202051280

Figure Lengend Snippet: IL‐6 secretion in HEI‐OC1 cells treated with 100 pg/ml LPS or 20 µM cisplatin ( n = 3 or 4 independent biological replicates). IL‐6 secretion in TLR4 −/− cells transfected with empty vector (EV) or mouse Tlr4 (m Tlr4 ) following treatment with 20 µM cisplatin ( n = 6 independent biological replicates). Il6 and Tlr4 transcript levels in HEI‐OC1 cells following treatment with 20 µM cisplatin for the indicated times ( n = 3 independent biological replicates). Data information: In all panels, data are presented as mean and standard deviation. Statistical comparisons to 0 h time point were assessed by 2‐way ANOVA. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 (Dunnett’s test). Source data are available online for this figure.

Article Snippet: HEI‐OC1 cells were transfected with a mouse Tlr4 expression clone (OriGene; MR210887) to test for complementation of the Tlr4 deletion strain.

Techniques: Transfection, Plasmid Preparation, Standard Deviation